Literature DB >> 24621987

Cross-cultural adaptation and preliminary test-retest reliability of the Italian version of the Complexity Rehabilitation Scale-Extended (13th version).

F Rodà1, M Agosti, E Corradini, F Lombardi, M Maini, R Brianti.   

Abstract

BACKGROUND: In Italy, the lack of appropriate use of intensive rehabilitative services is an acknowledged issue, as demonstrated by periodic epidemiological surveys. Rehabilitation activities are planned without considering the clinical complexity, known to be one of the most fundamental factors able to outline the real patients' needs on recently clinical practice rehabilitation guidelines. Alternative diagnostic systems become, therefore, necessary. For this reason, we would like to propose the Rehabilitation Complexity Scale - Extended version (RCS-E) within intensive rehabilitation units in Emilia Romagna. AIM: This study aims at submitting an Italian translation, cross-cultural adaptation and preliminary reliability evaluation of the Rehabilitation Complexity Scale Extended (13th Version) (RCS-E).
DESIGN: Face validity and test-retest reliability.
SETTING: The study was conducted in three different rehabilitation units of the Emilia Romagna region, Northern Italy. POPULATION: Ten expert physicians and 51 Intensive (code 56) rehabilitation in-patients were recruited.
METHODS: A cross-cultural adaptation of the scale was built from English into Italian, closely complying with international guidelines. Face validity and test-retest reliability were carried out to evaluate the comprehensibility and goodness of fit of the new scale.
RESULTS: An overall positive judgement was obtained with the face validity test. No significant differences were observed between the original and the adapted scale scoring. Internal consistency measured on 51 patients by Cronbach's alpha was 0.702 for the scale. The estimated SEM was 1.211. ICCconsistency was 0.702. Split-Half reliability and the Spearman-Brown prophecy were 0.633 and 0.775, respectively. Test-retest reliability of the RCS-E measured with ICCagreement was 0.903.
CONCLUSION: The adapted RCS-E provides a sensitive and reliable tool that appears to be suitable for measuring clinical complexity in Italian code 56 rehabilitation units. It is the first Italian version of the scale to be devised. CLINICAL REHABILITATION IMPACT: Further statistical validation will assess the Italian RCS-E as a possible instrument for guiding the patients' assignment to the rehabilitation settings that best suit their specific needs. These preliminary data represent the first step through this purpose.

Entities:  

Mesh:

Year:  2014        PMID: 24621987

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  4 in total

1.  Assessment of primary rehabilitation needs in neurological rehabilitation: translation, adaptation and face validity of the Danish version of Rehabilitation Complexity Scale-Extended.

Authors:  Thomas Maribo; Asger R Pedersen; Jim Jensen; Jørgen F Nielsen
Journal:  BMC Neurol       Date:  2016-10-21       Impact factor: 2.474

2.  Psychometric validation of the Italian Rehabilitation Complexity Scale-Extended version 13.

Authors:  Francesca Roda; Maurizio Agosti; Andrea Merlo; Maurizio Maini; Francesco Lombardi; Claudio Tedeschi; Maria Grazia Benedetti; Nino Basaglia; Mara Contini; Domenico Nicolotti; Rodolfo Brianti
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

3.  Cross-cultural adaptation and psychometric validation of the Korean version of rehabilitation complexity scale for the measurement of complex rehabilitation needs.

Authors:  Hoo Young Lee; Jung Hyun Park; Tae-Woo Kim
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

4.  Occupational Therapy in Complex Patients: A Pilot Randomized Controlled Trial.

Authors:  Martina Pellegrini; Debora Formisano; Veronica Bucciarelli; Margherita Schiavi; Stefania Fugazzaro; Stefania Costi
Journal:  Occup Ther Int       Date:  2018-09-03       Impact factor: 1.448

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.